| Leptin gene therapy in the fight against diabetes. | |
| | |
MedLine Citation:
|
PMID: 20690892 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
IMPORTANCE OF THE FIELD: The incidence of diabetes is increasing worldwide, yet current treatments are not always effective for all patient or disease types. AREAS COVERED IN THIS REVIEW: Here, we summarize the biologic and clinical roles of leptin in diabetes, and discuss candidate viral vectors that may be employed in the clinical use of central leptin gene therapy for diabetes. WHAT THE READER WILL GAIN: We discuss how studies on leptin, a regulator of the insulin-glucose axis, have significantly advanced our understanding of the roles of energy homeostasis and insulin resistance in the pathogeneses of metabolic syndrome and diabetes. Recent studies have demonstrated the long-term therapeutic effects of central leptin gene therapy in obesity and diabetes via decreased insulin resistance and increased glucose metabolism. Many of these studies have employed viral vectors, which afford high in vivo gene transduction efficiencies compared with non-viral vectors. TAKE HOME MESSAGE: Adeno-associated viral vectors are particularly well suited for central leptin gene therapy owing to their low toxicity and ability to drive transgene expression for extended periods. |
| | |
Authors:
|
Yuqing Wang; Akihiro Asakawa; Akio Inui; Ken-ichiro Kosai |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Expert opinion on biological therapy Volume: 10 ISSN: 1744-7682 ISO Abbreviation: Expert Opin Biol Ther Publication Date: 2010 Oct |
Date Detail:
|
Created Date: 2010-09-14 Completed Date: 2011-01-11 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101125414 Medline TA: Expert Opin Biol Ther Country: England |
Other Details:
|
Languages: eng Pagination: 1405-14 Citation Subset: IM |
Affiliation:
|
Kagoshima University Graduate School of Medical and Dental Sciences, Department of Gene Therapy and Regenerative Medicine, 8-35-1 Sakuragaoka, Kagoshima 890-8544, Japan. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Blood Glucose / metabolism Dependovirus / genetics Diabetes Mellitus / genetics, metabolism, therapy* Gene Therapy* / adverse effects Genetic Vectors Humans Insulin / blood Insulin Resistance Leptin / genetics, metabolism* Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Blood Glucose; 0/Leptin; 11061-68-0/Insulin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Cost analysis of flavocoxid compared to naproxen for management of mild to moderate OA.
Next Document: Canadian cost-effectiveness analysis of solifenacin compared to oxybutynin immediate-release in pati...